Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

ClinicalTrials.gov ID: NCT00452348

Public ClinicalTrials.gov record NCT00452348. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects With Asthma

Study identification

NCT ID
NCT00452348
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
628 participants

Conditions and interventions

Conditions

Interventions

  • Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID Drug
  • Fluticasone propionate 250 mcg BID Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2007
Primary completion
Mar 31, 2009
Completion
Mar 31, 2009
Last update posted
Dec 8, 2016

2007 – 2009

United States locations

U.S. sites
58
U.S. states
29
U.S. cities
57
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35209
GSK Investigational Site Birmingham Alabama 35294
GSK Investigational Site Mobile Alabama 36608
GSK Investigational Site Fresno California 93720
GSK Investigational Site Fullerton California 92835
GSK Investigational Site Huntington Beach California 92647
GSK Investigational Site Long Beach California 90808
GSK Investigational Site Los Angeles California 90048
GSK Investigational Site San Diego California 92120
GSK Investigational Site Stockton California 95207
GSK Investigational Site Vista California 92083
GSK Investigational Site Pueblo Colorado 81008
GSK Investigational Site Hudson Florida 34667
GSK Investigational Site South Miami Florida 33143
GSK Investigational Site Tampa Florida 33613
GSK Investigational Site Albany Georgia 31707
GSK Investigational Site Gainesville Georgia 30501
GSK Investigational Site Lawrenceville Georgia 30045
GSK Investigational Site Savannah Georgia 31406
GSK Investigational Site Coeur d'Alene Idaho 83814
GSK Investigational Site Evansville Indiana 47710
GSK Investigational Site Owensboro Kentucky 42301
GSK Investigational Site Sunset Louisiana 70584
GSK Investigational Site Rochester Minnesota 55905
GSK Investigational Site Chesterfield Missouri 63017
GSK Investigational Site Jefferson City Missouri 65101
GSK Investigational Site Missoula Montana 59808
GSK Investigational Site Lincoln Nebraska 68505
GSK Investigational Site Papillion Nebraska 68046
GSK Investigational Site Ocean City New Jersey 07712
GSK Investigational Site New York New York 10016
GSK Investigational Site Charlotte North Carolina 28207
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Fargo North Dakota 58104
GSK Investigational Site Canton Ohio 44718
GSK Investigational Site Oklahoma City Oklahoma 73120
GSK Investigational Site Lake Oswego Oregon 97035
GSK Investigational Site Medford Oregon 97504
GSK Investigational Site Collegeville Pennsylvania 19426
GSK Investigational Site Erie Pennsylvania 16508
GSK Investigational Site Philadelphia Pennsylvania 19102
GSK Investigational Site Cumberland Rhode Island 02864
GSK Investigational Site Charleston South Carolina 29406-7108
GSK Investigational Site Greenville South Carolina 29615
GSK Investigational Site Greer South Carolina 29651
GSK Investigational Site El Paso Texas 79903
GSK Investigational Site Houston Texas 77070
GSK Investigational Site Killeen Texas 76542
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Waco Texas 76712
GSK Investigational Site Murray Utah 84107
GSK Investigational Site Norfolk Virginia 23507
GSK Investigational Site Gig Harbor Washington 98335
GSK Investigational Site Tacoma Washington 98405
GSK Investigational Site Morgantown West Virginia 26505
GSK Investigational Site Greenfield Wisconsin 53228
GSK Investigational Site Madison Wisconsin 53972
GSK Investigational Site Milwaukee Wisconsin 53209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00452348, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 8, 2016 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00452348 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →